Gleason Group, Inc. Cue Biopharma, Inc. Transaction History
Gleason Group, Inc.
- $890 Million
- Q2 2025
A detailed history of Gleason Group, Inc. transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, Gleason Group, Inc. holds 6,000 shares of CUE stock, worth $4,980. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,000
Previous 6,000
-0.0%
Holding current value
$4,980
Previous $5,000
20.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding CUE
# of Institutions
50Shares Held
14.6MCall Options Held
10.1KPut Options Held
1.4K-
Bleichroeder LP New York, NY5MShares$4.15 Million1.56% of portfolio
-
Catalytic Wealth Ria, LLC Cambridge, MA3.33MShares$2.77 Million0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.32MShares$1.92 Million0.0% of portfolio
-
Black Rock Inc. New York, NY757KShares$628,0900.0% of portfolio
-
Geode Capital Management, LLC Boston, MA694KShares$575,9280.0% of portfolio
About Cue Biopharma, Inc.
- Ticker CUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,381,700
- Market Cap $29.4M
- Description
- Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...